Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Instil Bio Q3 2026 Results: Net Loss of $4.23M, Loss Narrows

Instil Bio, Inc. reported a net loss of $13.0 million for the nine months ended September 30, 2026, a significant reduction from the $63.5 million loss in the prior year period. The company is transitioning its strategy, having discontinued its lead product candidate AXN-2510 in January 2026, and is currently seeking to in-license or acquire new therapeutic candidates.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Net income-4.2-13.6
EPS (diluted, $ a share)$-0.62$-2.01

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: TIL. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Instil Bio, Inc.: key numbers

Share price
$5.75Close, Nov 16
Market cap
$39M
Shares outstanding
6.78MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Instil Bio, Inc.

All →
7:01 AM ET 8-K
Financial Results

Instil Bio Financial Results

Instil Bio reported third quarter 2026 financial results, highlighting a cash position of $67.1 million which is expected to fund operations through 2027. The company is transitioning to an asset-focused development model through subsidiaries while reporting a significantly narrowed net loss compared to the prior year period.

Term
Q3 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.